Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.

Currently, evidence to guide the choice between R-B and G-Clb in 1L unfit patients with CLL is limited, although a recent meta- analysis of PFS and OS results in five studies showed a trend towards better efficacy for G-Clb than R-B; 22 however, the difference was not significant despite a significant difference between G-Clb and other comparators such as R-Clb, Ofa-Clb, Clb, and fludarabine.

also in 53,322 other papers